AI-Powered Pathology Assessment Predicts Immunotherapy Success in Advanced Lung Cancer
Immune checkpoint inhibitors (ICIs) help only about 25–30% of patients with advanced non–small cell lung cancer (NSCLC) lacking EGFR or ALK alterations. Traditional biomarkers such as PD-L1 expression and tumor mutational burden (TMB) are imperfect, necessitating better predictors. Recent advances in artificial intelligence (AI) now allow analysis of digital pathology images to identify immune features […]
AI-Powered Pathology Assessment Predicts Immunotherapy Success in Advanced Lung Cancer Read More »